Research programme: peptide therapeutics - Toagosei
Latest Information Update: 28 Nov 2023
At a glance
- Originator Toagosei
- Class Antineoplastics; Peptides
- Mechanism of Action Sphingosine 1 phosphate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)
- 26 Oct 2019 Preclinical trials in Cancer in Japan (Parenteral)
- 26 Oct 2019 Pharmacodynamics data from a preclinical study in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019